Your shopping cart is currently empty

Rapirosiran sodium is a small interfering RNA conjugated with N-acetylgalactosamine that targets the mRNA of hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) expressed in the liver. Loss-of-function variants of HSD17B13 are associated with a reduced risk of chronic liver diseases.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Rapirosiran sodium is a small interfering RNA conjugated with N-acetylgalactosamine that targets the mRNA of hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) expressed in the liver. Loss-of-function variants of HSD17B13 are associated with a reduced risk of chronic liver diseases. |
| Synonyms | ALN-HSD sodium |
| Cas No. | 2755197-77-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.